Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Clene Inc. (CLNN) Message Board

Clene Inc. (NASDAQ: CLNN) CEO and CFO Present Corp

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 156
(Total Views: 130)
Posted On: 06/18/2024 5:09:07 PM
Avatar
Posted By: NetworkNewsWire
Clene Inc. (NASDAQ: CLNN) CEO and CFO Present Corporate Updates and Future Plans at 72nd Emerging Growth Conference

-Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience
- Clene has conducted several clinical trials to test the efficacy of CNM-Au8(R), focusing on the diseases amyotrophic lateral sclerosis and multiple sclerosis
- CNM-Au8 has shown a favorable safety profile, with over 650 collective years of subject exposure without any major safety signals attributed to CNM-Au8
- Negotiations are underway to extend the cash runway into 2025, including potential licensing deals and the exercise of warrants that could bring in up to $130 million in additional capital for the company

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently participated in the 72nd Emerging Growth Conference. EmergingGrowth.com is a leading independent small cap media portal that identifies companies with strong management teams, innovative products, focused strategy and overall potential for long-term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience.

The Emerging Growth Conference, moderated by award-winning journalist Ana Berry, is considered an effective way for public companies to engage with the investment community. Companies present new products, services, and make other announcements significant to their industry. During the event, Clene’s CEO presented the company’s groundbreaking asset, CNM-Au8, a suspension of gold nanocrystals designed to improve mitochondrial function and reduce oxidative stress. This novel treatment utilizes catalytic activity to enhance neuronal energy utilization, which is critical for maintaining brain function.

Neurodegenerative diseases such as ALS, Parkinson’s, and MS, are among the most challenging medical issues. These conditions involve the progressive degeneration of neurons. In ALS, degeneration of the motor neurons leads to compromised muscular functions, including breathing, swallowing, and motor skills. Despite various treatments, a definitive cure remains elusive. Clene is tackling this challenge with an innovative approach to neuroprotection.

Clene has conducted several clinical trials to test the efficacy of CNM-Au8, focusing on diseases like ALS and MS, and the results have been promising:

- RESCUE-ALS: A Phase 2 study involving 45 subjects showed significant improvements in survival rates and in delaying disease progression.
- HEALEY-ALS Platform Trial: This major study demonstrated a 70-90% risk reduction in death among participants, marking a significant breakthrough in ALS treatment.
- VISIONARY-MS Study: This study focused on MS patients with optic neuritis. Results indicated significant improvements in vision, cognition, and fine and gross motor skills, with continued benefits over time.
- Compassionate Use Program: Over 256 patients have participated in these programs, with many participants showing extended survival and improved quality of life compared to historical controls.

CNM-Au8 has shown a favorable safety profile, with over 650 collective years of subject exposure without any major safety signals. The most common side effects are mild to moderate, primarily gastrointestinal issues, and headaches.

Clene is preparing for a potential accelerated approval from the FDA, based on the promising data from its clinical trials. The company is also exploring partnerships and non-dilutive funding opportunities to support further development and commercialization of CNM-Au8.

According to Brown, as of the first quarter, Clene holds approximately $28 million in cash, with an average burn rate of $7 million per quarter. Negotiations are underway to extend the cash runway into 2025, including potential licensing deals and the exercise of warrants that could bring in up to $130 million in additional capital.

To watch a replay of Clene’s presentation at the Emerging Growth Conference, visit the conference’s YouTube at https://nnw.fm/5itnB.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer




(0)
(0)




Clene Inc. (CLNN) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us